CoChat

Metabolic responses and benefits of glucagon‐like peptide‐1 (GLP‐1) receptor ligands

Open access
Tanday, Neil, Flatt, Peter R., Irwin, Nigel · 2022 · British Journal of Pharmacology
Cited by 41

The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.

Abstract

Glucagon‐like peptide‐1 (GLP‐1) is an incretin hormone that has undergone a revolutionary turnaround from discovery to clinically approved therapeutic. Rapid progress in drug design and formulation has led from initial development of short‐ and long‐acting drugs suitable for daily or weekly parenteral administration, respectively, through to the most recent approval of an orally active GLP‐1 agent. The current review outlines the biological action profile of GLP‐1 including the various beneficial metabolic responses in pancreatic and extra‐pancreatic tissues, including the gastrointestinal tract, liver, bone and kidney as well as the reproductive cardiovascular and CNS. We then briefly consider clinically approved GLP‐1 receptor ligands and recent advances in this field. Given the sustained evolution in the area of GLP‐1 drug development and excellent safety profile, as well as the plethora of metabolic benefits, clinical approval for use in diseases beyond diabetes and obesity is very much conceivable. LINKED ARTICLES: This article is part of a themed issue on GLP1 receptor ligands (BJP 75th Anniversary). To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v179.4/issuetoc

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/bph.15485

Cites

59 of 59 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 59 references

Cited by

Metadata

Authors
Tanday, N., Flatt, P. R., & Irwin, N.
Venue
British Journal of Pharmacology
Publisher
Wiley
Published
2021-05-10
Volume
179
Issue
4
Pages
526-541
ISSN
  • 0007-1188 (ISSN-L)
  • 1476-5381
OpenAlex
W3151949017
Cited by
41
References
59
FWCI
3.43
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.